The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention
dc.contributor.author | Texter, Michele | en_US |
dc.contributor.author | Lees, Robert S. | en_US |
dc.contributor.author | Pitt, Bertram | en_US |
dc.contributor.author | Dinsmore, Robert E. | en_US |
dc.contributor.author | Uprichard, Andrew C. G. | en_US |
dc.date.accessioned | 2006-09-11T15:03:05Z | |
dc.date.available | 2006-09-11T15:03:05Z | |
dc.date.issued | 1993-04 | en_US |
dc.identifier.citation | Texter, Michele; Lees, Robert S.; Pitt, Bertram; Dinsmore, Robert E.; Uprichard, Andrew C. G.; (1993). "The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention." Cardiovascular Drugs and Therapy 7(2): 273-282. <http://hdl.handle.net/2027.42/44614> | en_US |
dc.identifier.issn | 0920-3206 | en_US |
dc.identifier.issn | 1573-7241 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/44614 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8357782&dopt=citation | en_US |
dc.description.abstract | The rationale, trial design, and statistical aspects of QUIET, the QUinapril Ischemic Event Trial, are described. QUIET is a prospective, double-blind placebo-controlled study that will assess the ability of the angiotensin-converting enzyme (ACE) inhibitor quinapril to reduce the rate of cardiac ischemic events and to slow or prevent the development of coronary artery atherosclerosis as assessed by serial angiography in a normolipidemic population without left ventricular dysfunction. The study began in September 1991 and has completed recruitment with 1740 patients across 38 centers (28 U.S., 4 Canada, 6 Europe) by the end of 1992. Patients are randomized to 20 mg of quinapril or placebo once daily and continue in the study for 3 years. Study completion is projected for 1995. | en_US |
dc.format.extent | 965734 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Cardiology | en_US |
dc.subject.other | Clinical Trials | en_US |
dc.subject.other | Coronary Disease | en_US |
dc.subject.other | Angiotensin-coverting Enzyme Inhibitors | en_US |
dc.subject.other | Atherosclerosis | en_US |
dc.subject.other | Drug Therapy | en_US |
dc.subject.other | Ischemia | en_US |
dc.subject.other | Quinapril | en_US |
dc.title | The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Cardiology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, 48105, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Boston Heart Foundation, Cambridge, Massachusetts | en_US |
dc.contributor.affiliationother | Boston Heart Foundation, Cambridge, Massachusetts | en_US |
dc.contributor.affiliationother | Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, 48105, Ann Arbor, MI | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 8357782 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/44614/1/10557_2004_Article_BF00878518.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00878518 | en_US |
dc.identifier.source | Cardiovascular Drugs and Therapy | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.